|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
|
CN107501407B
(zh)
|
2007-03-30 |
2022-03-18 |
Ambrx公司 |
经修饰fgf-21多肽和其用途
|
|
CN102361647B
(zh)
|
2009-01-23 |
2018-02-16 |
诺沃-诺迪斯克有限公司 |
具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
|
|
WO2011154349A2
(en)
*
|
2010-06-08 |
2011-12-15 |
Novo Nordisk A/S |
Fgf21 analogues and derivatives
|
|
EP2460527A1
(en)
*
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
CN103124562A
(zh)
*
|
2010-06-08 |
2013-05-29 |
诺沃—诺迪斯克有限公司 |
Fgf21的类似物和衍生物
|
|
CN105601748B
(zh)
|
2011-07-01 |
2021-08-27 |
恩格姆生物制药公司 |
用于代谢病症和疾病治疗的组合物、应用和方法
|
|
EP2548570A1
(en)
*
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
UY34347A
(es)
*
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
|
CN104203977A
(zh)
|
2012-02-15 |
2014-12-10 |
诺和诺德A/S（股份有限公司） |
结合肽聚糖识别蛋白1的抗体
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
JP6411218B2
(ja)
|
2012-02-15 |
2018-10-24 |
ノヴォ ノルディスク アー／エス |
骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
|
|
TW201420606A
(zh)
*
|
2012-08-22 |
2014-06-01 |
Lilly Co Eli |
同源二聚體蛋白
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
HK1214832A1
(zh)
|
2012-11-28 |
2016-08-05 |
恩格姆生物制药公司 |
用於代謝病症和疾病治療的組合物和方法
|
|
AU2013366692B2
(en)
|
2012-12-21 |
2017-11-23 |
Sanofi |
Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
|
|
ES2915851T3
(es)
|
2012-12-27 |
2022-06-27 |
Ngm Biopharmaceuticals Inc |
Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
JP6475233B2
(ja)
|
2013-06-20 |
2019-02-27 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
CA2927592C
(en)
|
2013-10-28 |
2020-08-18 |
Ngm Biopharmaceuticals, Inc. |
Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
PE20170256A1
(es)
|
2014-01-24 |
2017-04-22 |
Ngm Biopharmaceuticals Inc |
Proteinas de union y sus metodos de uso
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
AU2015277438B2
(en)
|
2014-06-16 |
2020-02-27 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
EA037844B1
(ru)
|
2014-07-17 |
2021-05-27 |
Ново Нордиск А/С |
Сайт-направленный мутагенез антител к trem-1
|
|
RU2729161C2
(ru)
|
2014-10-23 |
2020-08-04 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
|
|
CN114805532A
(zh)
|
2014-10-24 |
2022-07-29 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
JP6730278B2
(ja)
|
2014-11-27 |
2020-07-29 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
WO2016097108A1
(en)
|
2014-12-17 |
2016-06-23 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
AR103246A1
(es)
|
2014-12-23 |
2017-04-26 |
Novo Nordiks As |
Derivados de fgf21 y sus usos
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
EA037478B1
(ru)
|
2015-08-04 |
2021-04-01 |
Дьюк Юниверсити |
Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
|
|
KR102668200B1
(ko)
|
2015-10-28 |
2024-05-23 |
주식회사유한양행 |
지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
|
|
KR102670157B1
(ko)
*
|
2015-10-28 |
2024-05-29 |
주식회사유한양행 |
이중 작용 단백질 및 이를 포함하는 약학적 조성물
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
MX2018014475A
(es)
*
|
2016-05-25 |
2019-05-23 |
Univ Texas |
Métodos y composiciones para el tratamiento de trastornos secretorios.
|
|
WO2017210476A1
(en)
|
2016-06-01 |
2017-12-07 |
Duke University |
Nonfouling biosensors
|
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技（上海）有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
|
CN106317226B
(zh)
|
2016-08-19 |
2017-09-05 |
安源医药科技（上海）有限公司 |
用于构建融合蛋白的连接肽
|
|
US11123438B2
(en)
|
2016-08-19 |
2021-09-21 |
Ampsource Biopharma Shanghai Inc. |
Linker peptide for constructing fusion protein
|
|
CA3034399A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
WO2018053201A1
(en)
|
2016-09-14 |
2018-03-22 |
Duke University |
Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
|
|
JP2020500150A
(ja)
|
2016-09-23 |
2020-01-09 |
デューク ユニバーシティ |
下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
|
|
MX2019005380A
(es)
|
2016-11-10 |
2019-08-12 |
Yuhan Corp |
Composicion farmaceutica que comprende proteinas de fusion para prevenir o tratar la hepatitis, la fibrosis hepatica y la cirrosis hepatica.
|
|
EP3552022B1
(en)
*
|
2016-11-25 |
2021-06-09 |
Implexion AB |
Metabolic disorders
|
|
WO2018132732A1
(en)
|
2017-01-12 |
2018-07-19 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
WO2018166461A1
(en)
|
2017-03-14 |
2018-09-20 |
Sunshine Lake Pharma Co., Ltd. |
Dual-target fusion proteins comprising the fc portion of an immunoglobulin
|
|
CN108619490A
(zh)
*
|
2017-03-22 |
2018-10-09 |
天士力医药集团股份有限公司 |
一种长效化突变的人源成纤维生长因子的新用途
|
|
US11560416B2
(en)
|
2017-04-21 |
2023-01-24 |
Yuhan Corporation |
Method for producing dual function proteins and its derivatives
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
WO2019006374A1
(en)
|
2017-06-30 |
2019-01-03 |
Duke University |
ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
|
|
CN109836504B
(zh)
*
|
2017-11-24 |
2022-08-02 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
|
WO2019119673A1
(zh)
*
|
2017-12-19 |
2019-06-27 |
北京吉源生物科技有限公司 |
一种双基因修饰的干细胞及其用途
|
|
CN109942696A
(zh)
*
|
2017-12-21 |
2019-06-28 |
中国药科大学 |
长效化胰高血糖素样肽－1（glp－1）类似物及其应用
|
|
CN110028587B
(zh)
*
|
2018-01-11 |
2021-10-08 |
安源医药科技（上海）有限公司 |
用于调节血糖和脂质的增效型双功能蛋白
|
|
WO2019147954A1
(en)
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
AU2019218147B2
(en)
|
2018-02-08 |
2023-06-08 |
Sunshine Lake Pharma Co., Ltd. |
FGF21 variant, fusion protein and application thereof
|
|
WO2019195126A1
(en)
|
2018-04-02 |
2019-10-10 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
|
EP3788343B1
(en)
|
2018-04-30 |
2024-03-27 |
Duke University |
Stimuli-responsive peg-like polymer-based drug delivery platform
|
|
US11649275B2
(en)
|
2018-08-02 |
2023-05-16 |
Duke University |
Dual agonist fusion proteins
|
|
US12594347B2
(en)
|
2018-09-07 |
2026-04-07 |
Duke University |
Nanoparticulate drug delivery systems
|
|
CN112351994B
(zh)
*
|
2019-04-11 |
2024-06-07 |
江苏豪森药业集团有限公司 |
一种多受体激动剂及其医药用途
|
|
CN111944055B
(zh)
|
2019-05-16 |
2022-08-02 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的融合蛋白
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
CN112279920B
(zh)
*
|
2019-07-25 |
2024-01-16 |
安源医药科技（上海）有限公司 |
FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
|
|
CN113728013B
(zh)
*
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
|
WO2024165571A2
(en)
|
2023-02-06 |
2024-08-15 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
KR20250167609A
(ko)
|
2023-03-30 |
2025-12-01 |
노보 노르디스크 에이/에스 |
융합 화합물 및 그 용도
|
|
WO2025125576A2
(en)
|
2023-12-15 |
2025-06-19 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2025133348A1
(en)
|
2023-12-22 |
2025-06-26 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
EP4686757A1
(en)
|
2024-07-31 |
2026-02-04 |
e-therapeutics PLC |
Inhibitors of expression and/or function
|
|
WO2025196502A1
(en)
|
2024-03-20 |
2025-09-25 |
North Carolina Agricultural & Technical State University |
Choline kinase inhibitors as a therapeutic treatment for obesity
|